Parallel trials with other ATR inhibitors, including Ceralasertib, Elimusertib, Gartisertib, and M1774, have reported favorable tolerability and encouraging antitumor activity in triple-negative breast cancer, ovarian cancer, and non-small cell lung cancer (17–19). This evidence concerns the gene ATR and ovarian carcinoma.